Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the RNA Targeting Small Molecules Therapeutics Market Grown from 2024 to 2025?

In recent times, the market for RNA targeting small molecules therapeutics has experienced exponential growth. The market, which was worth $6.1 billion in 2024, is forecasted to expand to $7.87 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. Factors such as advancements in drug discovery and development, increasing number of RNA-related diseases, both government and private sector funding, interest from the pharmaceutical industry, and successful narratives of RNA therapeutics have contributed to the growth recorded during the historical period.

What Growth Rate Is Anticipated for the RNA Targeting Small Molecules Therapeutics Market in the Coming Years?

The market for RNA targeting small molecule therapeutics is projected to experience an immense expansion in the forthcoming years, with a valuation of $22.36 billion anticipated by 2029, growing at a CAGR of 29.8%. Factors contributing to this surge during the forecast period include the development of precision medicine and individualized treatment approaches, the growing identification of RNA biomarkers, broadening of RNA target spectrum, augmented funding and investments, and applications in rare disease treatments. Further trends predicted for the forecast period are advancements in screening technologies, dominance of antisense oligonucleotides, emergent small molecule RNA binders, RNA therapeutics application for neurological disorders, and gene editing utilizing the crispr-cas9 technique.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

Who Are the Leading Companies in the RNA Targeting Small Molecules Therapeutics Market?

Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

What Are the Key Drivers of the RNA Targeting Small Molecules Therapeutics Market?

The escalating incidence of cancer is predicted to accelerate the growth trajectory of the RNA-targeting small molecule therapeutics market. Cancer encompasses diseases that can originate in almost any tissue or organ when irregular cells multiply beyond control, surpass their typical confines, and spread to other organs or impinge on nearby body parts. The treatment for cancer involves the use of RNA-targeting small molecules that are designed and studied for the purpose of specifically targeting RNA molecules linked with cancer. For instance, studies conducted by the American Cancer Society, a US-based health organization, in January 2022 revealed that there are anticipated to be 609,360 cancer fatalities and 1.9 million fresh cases of cancer in the US in 2022. This approximates to around 1,670 deaths each day. Consequently, the escalating incidence of cancer is stimulating the expansion of the RNA-targeting small molecule therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12253&type=smp

What Are the Key Market Segments in the RNA Targeting Small Molecules Therapeutics Industry?

The RNA targeting small molecules therapeutics market covered in this report is segmented –

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings

2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications

3) By Application: Drug Discovery, Oncology Research, Disease Identification

4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation

2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides

3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers

4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

What Are the Latest Trends in the RNA Targeting Small Molecules Therapeutics Market?

One of the prevalent trends in the RNA-targeting small molecule therapeutics market is the formation of strategic alliances. Major players in the market are increasingly entering into collaborations to foster a new relationship whereby multiple entities produce innovative items. For example, Otsuka Pharmaceutical Co. Ltd., a pharmaceutical manufacturer from Japan, joined forces with xFOREST Therapeutics Co. Ltd., another Japanese company specializing in drug discovery platforms, in June 2022. This partnership allows xFOREST to provide Otsuka with its Forest technology to expedite small-molecule drug discovery research focusing on RNA structures. Furthermore, in April 2024, Ipsen, a biopharmaceutical firm from France, partnered with Skyhawk Therapeutics, a US-based clinical-stage biotechnology company offering RNA-targeting small molecule therapeutics. Through this partnership, Ipsen sought to produce RNA-targeting small molecule medicines for rare neurological disorders while employing various data sets to pinpoint and develop small molecules capable of modulating RNA.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Are the Key Regional Markets in the RNA Targeting Small Molecules Therapeutics Industry?

North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253

This Report Delivers Insight On:

1. How big is the rna targeting small molecules therapeutics market, and how is it changing globally?

2. Who are the major companies in the rna targeting small molecules therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the rna targeting small molecules therapeutics market right now?

4. Which products or customer segments are growing the most in the rna targeting small molecules therapeutics market?

5. What factors are helping or slowing down the growth of the rna targeting small molecules therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model